Gilead Sciences, Inc. secures final regulatory approvals for its acquisition of Arcellx, Inc. and extends tender offer deadline to April 27, 2026.
Written By: Pharmacally Medical News Desk
Gilead Sciences, Inc. has obtained all required regulatory approvals for its planned acquisition of Arcellx, Inc. and has extended its tender offer to April 27, 2026. The final approval came from the Australian Competition and Consumer Commission, which cleared the transaction subject to a 14-day waiting period ending on April 27, while the Austrian competition review period has expired without objection. The regulatory condition tied to the transaction will be satisfied upon expiration of this waiting period.
The tender offer remains subject to customary closing conditions, including the requirement that a majority of Arcellx shares be tendered. As of April 16, 2026, approximately 10.27 million shares, representing about 17.5% of outstanding shares, had been validly tendered and not withdrawn, according to Computershare Trust Company, N.A.. Shareholders who have already tendered their shares are not required to take further action following the extension.
Under the terms of the offer, Arcellx shareholders will receive $115.00 per share in cash along with one contingent value right (CVR), which provides a potential additional payment of $5.00 in cash by March 31, 2030, if cumulative global sales of anito-cel exceed $6 billion by the end of 2029. The transaction is approaching completion, pending satisfaction of the remaining shareholder-related conditions.
The acquisition strengthens Gilead’s position in cell therapy by securing full control of Arcellx’s lead clinical asset, anito-cel, a BCMA-directed CAR-T therapy for relapsed or refractory multiple myeloma, along with its D-Domain technology platform. Already co-developed with Gilead’s Kite unit, the therapy is in late-stage evaluation and under U.S. regulatory review, with the deal consolidating development, manufacturing, and commercialization within Gilead.
References